Boonpiyathad Tadech, Yimsawad Sittipong, Sangasapaviriya Atik
J Med Assoc Thai. 2016 Jan;99(1):51-7.
Asthma is a chronic respiratory disease that affects patients' quality of life and work performance. The cost of asthma treatment is a global economic burden. The costs include the direct medical costs and the indirect costs, such as the loss of productivity, which is difficult to quantify.
Analyze the cost of asthma treatment in Thailand.
Seventy-four asthmatic patients who had exacerbation were enrolled in the present study. Self-answer questionnaires were completed by the subjects including characteristics, socioeconomic factors, and level of asthma control by asthma control test (ACT) score. We evaluated the cost of asthma treatment calculated from direct medical, direct non-medical, and indirect medical costs.
The average total cost per month was 2,752 Thai baht (US$ 86). The direct medical, direct non-medical, and indirect medical costs were 52.39%, 20.73%, and 26.88%, respectively. The direct medical costs accounted for quick-relief medications 11.91% and control medications 36.85% of the total medical cost. Loss of productivity, loss of work caused by asthma exacerbation, was the majority cost of non-medical costs. The average cost of treatment in uncontrolled was higher than partly controlled asthmatic patients but without significant difference. Healthcare payment system and age range affected the total costs of asthma treatment.
The direct non-medical costs and indirect medical costs tend to play an important role of asthma treatment. The data suggested that cost savings could be achieved by improving asthma control.
哮喘是一种慢性呼吸道疾病,会影响患者的生活质量和工作表现。哮喘治疗费用是一项全球经济负担。这些费用包括直接医疗费用和间接费用,如生产力损失,而生产力损失难以量化。
分析泰国哮喘治疗的费用。
本研究纳入了74名哮喘加重患者。受试者完成了自填式问卷,内容包括特征、社会经济因素以及通过哮喘控制测试(ACT)评分得出的哮喘控制水平。我们评估了由直接医疗、直接非医疗和间接医疗费用计算得出的哮喘治疗费用。
每月平均总费用为2752泰铢(86美元)。直接医疗、直接非医疗和间接医疗费用分别占52.39%、20.73%和26.88%。直接医疗费用中,急救药物占总医疗费用的11.91%,控制药物占36.85%。生产力损失,即哮喘加重导致的工作损失,是非医疗费用中的主要部分。未得到控制的哮喘患者的平均治疗费用高于部分得到控制的哮喘患者,但差异无统计学意义。医疗支付系统和年龄范围影响哮喘治疗的总费用。
直接非医疗费用和间接医疗费用在哮喘治疗中往往起着重要作用。数据表明,通过改善哮喘控制可以实现成本节约。